Abbott has launched the AVEIR dual chamber (DR) leadless pacemaker system, the first technology of its kind, in India. Designed to treat bradycardia, a condition where the heart beats too slowly, this system replaces traditional pacemakers that require surgical pockets and leads to connect the device to the heart.
According to the company, the system consists of two separate devices: the AVEIR VR for the lower heart chamber and the AVEIR AR for the upper chamber. Each device is approximately one-tenth the size of a standard pacemaker and smaller than a AAA battery. They are implanted directly into the heart’s interior via a minimally invasive catheter procedure. A “fixation helix” screw-in mechanism secures the devices, allowing for potential retrieval or replacement if medical needs change.
A key innovation is the implant-to-implant (technology, which enables the two devices to communicate in real time.) Using high-frequency pulses transmitted through the body’s blood, the system synchronizes the atrium and ventricle beat by beat. This method is more power-efficient than Bluetooth or radio frequency alternatives. Prior to this technology, leadless options were limited to single-chamber support because of the difficulty of synchronizing two independent devices without wires. This development is particularly significant for regions like India, where approximately one-third of pacemaker recipients require dual-chamber pacing.
Clinical data from an Investigational Device Exemption (IDE) study, published in The New England Journal of Medicine, supported the system’s safety and efficacy. The study reported a 98.3% implant success rate and found that over 97% of patients achieved successful atrio-ventricular synchrony. The system also remained functional across various physical activities.
Established in India in 1910, Abbott is the oldest American life science company operating in India which now has 12,000 local employees.
Last updated: December 26th, 2025
